The human T-lymphotropic virus type I (HTLV-I) is a retrovirus that is usually transmitted vertically in endemic areas, which can lead to Adult T-cell leukemia-lymphoma (ATLL) in~5% of carriers [1] . ATLL has four distinct clinical forms: the acute and lymphomatous are the most common and aggressive subtypes [2] with median overall survival (OS) of 8-12 months [3] . Outcomes remain poor despite chemotherapy [4] , autologous [5] , allogeneic [6] including cord blood [7] hematopoietic stem cell transplantation (HSCT). We present the first case of ATLL treated with syngeneic HSCT from HTLV-1 seropositive twin which remains in remission for more than 3 years post transplant.
A 48-year-old Ghanaian woman originally presented to an emergency room with lower abdominal pain, radiating to the back, and progressive back pain, at time where a CT scan of the abdomen and pelvis revealed numerous sclerotic vertebral lesions and a lytic left iliac wing lesion. An MRI of the spine showed diffuse bone marrow infiltration with intraspinal metastatic involvement at T9 with tumors surrounding the cord and presumed cord compression, as well as significant infiltration of the C4 vertebral body, narrowing of the spinal canal at T12 from tumor and involvement of the L3, L4, L5, and the sacrum. Given the concern for cord compression, she was treated with high-dose steroids, which were discontinued after patient remained without neurological deficits for a week. MRI of the brain showed no evidence of intracranial malignancy and a lumbar puncture was negative for malignant cells.
A CT-guided biopsy of the L3 vertebra revealed a hypercellular marrow with 100% cellularity and replacement of the marrow by plasmacytoid appearance of neoplastic cells, which stained positive for CD30, CD4, CD25, CD43, with weak staining of CD45, CD2, and CD3 but were negative for kappa, lambda, CD138, AE1/AE3, CAM5.2, S100, Gamma, synaptophysin, chromogranin, desmin, PLAP, CD99, HV8, CD68, CD15, ALK, CD8, CD20, CD798, PAX5, and CD117. Overall immunophenotype and morphology were consistent with ATLL. Clonal T-cell receptor beta and gamma gene rearrangement was identified. Serology for HTLV-1 was positive. A bone marrow biopsy revealed no evidence of involvement. She presented to our institution for further management. Upon presentation she complained of persistent back pain, severe fatigue, anorexia, night sweats, and a~5 kg weight loss over the last 2 months. Her physical examination was remarkable for a lethargic, deconditioned, and diaphoretic African female, with tenderness to her cervical and lumbar spine. Labs were significant for a mild normocytic anemia with a hemoglobin of 7.9 g/dL, as well as an elevated lactate dehydrogenase of 1389 U/L, and a uric acid level of 6.7 mg/ dL. The remainder of her blood work-including comprehensive metabolic panel, complete blood count with differential and HIV testing-was otherwise unremarkable. The patient was also noted to have been exposed to hepatitis B, with a positive core antibody. Staging PET-CT scan showed hypermetabolic right external iliac chain lymphadenopathy, SUV 4.1 and increased hypermetabolism in the osseous structures with diffuse mottled sclerotic changes in the regions identified on prior CT scan and MRI suspicious for malignancy. A repeat MRI of the spine also showed illdefined linear enhancement of the leptomeninges at T12-L1 level suspicious for leptomeningeal disease.
The patient began treatment with dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, and prednisone(DA-EPOCH) alternating with high-dose methotrexate (HD-MTX) and intrathecal cytarabine (ITaraC), in addition to intravenous hydration and allopurinol for tumor lysis syndrome prophylaxis, entecavir, acyclovir, and trimethoprim-sulfamethoxazole for hepatitis B reactivation, Zoster, and Pneumocystis jiroveci pneumonia (PCP) prophylaxis, respectively. PET-CT scan after two cycles of chemotherapy revealed resolution of prior heterogeneous FDG avid osseous lymphoma, as well as resolution of FDG avidity and decreased size of right external iliac chain lymph nodes. Repeat MRI of the spine showed unchanged ill-defined linear enhancement of the leptomeninges at T12-L1 level. The patient completed six cycles of DA-EPOCH with HD-MTX and IT-araC. A PET/CT scan performed at the end of treatment confirmed a continued complete response.
The patient was referred to the transplant service for consideration for consolidation with allogeneic stem cell transplant. She had no matched related or unrelated donors, except for an identical twin who was sero-positive for HTLV-1. After a multi-disciplinary discussion, the HTLV-1 positive syngeneic graft was favored over autologous due to risk of recurrence, and over cord blood alternatives due to significant risks for complications related to social and language barriers. The patient underwent a syngeneic HSCT from her twin sister. A myeloablative conditioning regimen with 1320 cGY of total body irradiation (TBI) and etoposide 60 mg/Kg × 1 was administered. Monozygosity with the twin was confirmed based on a compatible history, and comprehensive testing of human leukocyte antigens (HLA), short-tandem repeats (STR), single-nucleotide polymorphisms (SNP), and extended red blood cell phenotyping, which all resulted as identical for both siblings. As such, no graft-versus-host disease prophylaxis was used.
Interestingly, the post-transplant course was complicated by early severe upper and lower gastrointestinal acute graftversus-host disease (GVHD), grade 4, which started on day +17, confirmed by upper and lower endoscopic biopsies revealing epithelial injury and apoptotic debris associated pauci-inflammatory reactions. Infectious work-up (including tissue testing for H pylori, CMV, EBV, and adenovirus) was negative and the patient rapidly improved after initiation of intravenous methylprednisolone 1 mg/kg every 12 h, with complete resolution of symptoms within 48 h of starting systemic corticosteroids. Patient was subsequently placed on prednisone, budesonide, and tacrolimus. All of these agents were successfully tapered off by day +86 post transplant, with no subsequent occurrence of GVHD. CMV viremia while on immunosuppression was controlled with oral valganciclovir. The remainder of her post-transplant course was essentially unremarkable. She has remained without clinical, radiographic, or hematopathologic evidence of disease recurrence after 3 years of follow-up post transplant.
Discussion
We present the first case of syngeneic HSCT in ATLL from a HTLV-1 seropositive donor. The pathophysiology of ATLL is not fully understood but it is thought to arise from a multi-step carcinogenesis process broadly involving early epigenetic abnormalities consisting of polycomb repressive complex 2 (PRC2) hyperactivation with genome-wide H3K27 me3 accumulation, and genetic alterations impacting the T cell receptor-NF-kB signaling [8] . A prior study involving HLTV-1 seropositive monozygotic twins suggested that discordant clinical outcomes in those individuals resulted from the difference in infected proviral sequences in the case of HTLV-1-associated myelopathy/tropical spastic parapersis (HAM/TSP) [9] . Our case, interestingly, suggests that immune-mediated epigenetic factors influence ATLL tumorigenesis in HTLV-1 infected individuals, as our patient with ATLL appeared to have distinct immune constitution from her seropositive monozygotic twin, as suggested by: (a) the absence of tumorigenesis in her seropositive twin; (b) the absence of relapse > 3 years after syngeneic HSCT; and (c) the occurrence of acute graftversus-host disease (aGVHD). The occurrence of aGVHD and chronic GVHD may contribute to lower risk for relapse in allogeneic HSCT [10] , and GVHD-like syndromes in syngeneic HSCT recipients have been recognized for almost four decades, although occurring less frequently [11] . In autologous HSCT, attempts at inducing autologous GVHD in order to further decrease relapse risk have not been very successful in patients with high-risk lymphoma [12] .
Although dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH) is an active regimen against ATLL [4] , current therapies offer poor overall outcomes, with only few prospective studies reporting best long-term disease-free survival (DFS) and OS with allogeneic HSCT, despite hightreatment related mortality, through evidence of graftversus-HTLV-1 and graft-versus-tumor effect [13] [14] [15] . The greatest experience comes from the Japan Clinical Oncology Group (JCOG) with the largest registry study of 1594 patients with ATLL included 1270 patients with acute and lymphoma types, of which 277 received allogeneic HSCT, with median OS of 5.9 months from HSCT [3] . Patients who received allogeneic HSCT in first remission had better outcomes with median OS of 22 months. Reduced-intensity (RIC) and myeloablative (MAC) conditioning regimens have been used, with variable success: 31% DFS and 36% OS with RIC [16] ; 33.8% DFS and 45.3% OS with MAC [6] . Across all studies, almost all relapses occurred within the first 2 years, with the majority occurring within 1 year after transplant [6, 16] . As such, our patient who remains without evidence of disease recurrence more than 3 years post transplant is unlikely to relapse.
In conclusion, our case suggests that a syngeneic graft can significantly reduce post-transplant relapse-risk even in the absence of disparity in histocompatibility genes seen with non-syngeneic allogeneic transplants mainly through the acquisition of an altered immune system constitution. Both syngeneic and non-syngeneic allogeneic HSCT from a HTLV-1 seropositive donor could be considered as a potentially curative option for patients with HTLV-1 associated ATLL. The low risk of relapse is likely due to enhanced graft-versus-virus and graft-versus-tumor effect.
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